Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients

CompletedOBSERVATIONAL
Enrollment

703

Participants

Timeline

Start Date

July 19, 2013

Primary Completion Date

December 4, 2018

Study Completion Date

December 4, 2018

Conditions
Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)
Trial Locations (12)

14263

Roswell Park Cancer Institute, Buffalo

19104

University of Pennsylvania Abramson Cancer Center, Philadelphia

21201

University of Maryland, Baltimore

27710

Duke University, Durham

44195

Cleveland Clinic, Cleveland

60611

Northwestern Memorial Hospital, Chicago

63110

Washington University School of Medicine, St Louis

84112

University of Utah Huntsman Cancer Institute, Salt Lake City

94305

Stanford Cancer Institute, Stanford

98109

Fred Hutchinson Cancer Research Center, Seattle

SCCA Network Clinics, Seattle

07601

The John Theurer Cancer Center at Hackensack University Medical Center, Hackensack

All Listed Sponsors
collaborator

Patient-Centered Outcomes Research Institute

OTHER

collaborator

American Cancer Society, Inc.

OTHER

lead

Fred Hutchinson Cancer Center

OTHER

NCT01929408 - Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients | Biotech Hunter | Biotech Hunter